|
|
||||||||
Department of Cardiothoracic and Vascular Surgery, Deutsches Herzzentrum Berlin, Augustenburger Platz 1, Berlin, 13353 Germany
(Email: siniawski@dhzb.de).
| The first 20% of the full text of this article appears below. |
The article by Eichinger and colleagues [1] reports their experience with 20-year longevity of the St. Jude Biocor bioprosthesis (St. Jude Medical, Inc, St. Paul, MN) in terms of the incidence of valve deterioration, thrombogenicity, endocarditis, and related health events (ie, basic information for valve substitute assessment).
These two decades of follow-up represent an era in which biological prostheses generally won the battle against mechanical substitutes. The reason for this trend in cardiosurgery is an expectation of better quality of life and lower risk of morbidity and mortality (especially in older populations) after biological
Related Article
Ann. Thorac. Surg. 2008 86: 1204-1210.
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |